Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice call Ed, it hasn't recived much volume yet. When it does it should run.
Thanks dragonfly!
Nice board, lots of usefull links here.
Question? Is there a particular form that is file for the reinstatement of a company?
Thanks!
GLTA
begging to UT a little.
ANN ARBOR, MI, Jan 12, 2007 (MARKET WIRE via COMTEX) -- Pipex Pharmaceuticals, Inc. (PPXP : PPXP News , chart, profile, more
Last:
PPXP, , ) , a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has completed the previously disclosed planned acquisition of its majority-owned subsidiary, Effective Pharmaceuticals, Inc. (EPI). As a result of this acquisition, Pipex has gained broader control of Effective Pharmaceuticals, Inc.'s (EPI) lead products, Anti-CD4 802-2 and CORRECTA(TM), both of which are in phase II clinical stage of development.
Steve H. Kanzer, Chairman and Chief Executive Officer of Pipex stated, "Consummation of this transaction gives Pipex improved economics and greater control with respect to our important Anti-CD4 802-2 and CORRECTA programs."
Anti-CD4 802-2
Pipex is developing a series of rationally designed small molecule/peptidomimetic inhibitors of the highly important CD4 co-receptor of T-cells. Pipex's lead anti-CD4 molecule, Anti-CD4 802-2, is a cyclic heptapeptide that has demonstrated efficacy in a number of animal models of multiple sclerosis and other animal models of autoimmune disease and is currently nearing completion of a dose ranging phase I/II clinical trial for the prevention of graft-versus-host disease (GvHD), a life threatening transplant disease. Preliminary data from the study appears to show suppression of GvHD in treated patients. In addition, Pipex plans to broaden the therapeutic utility of these molecules through additional preclinical and clinical studies for other CD4-mediated diseases. Some of these diseases might include, induction of immune tolerance to widely marketed exogenous biologic agents, multiple sclerosis, psoriasis, transplant-related ischemic reperfusion injury, lupus, asthma and rheumatoid arthritis. Anti-CD4 802-2 may represent the first clinical stage, non-biologic molecule capable of inducing immune tolerance for a variety of CD4-mediated autoimmune diseases. Anti-CD4 802-2 has also demonstrated oral activity animal models of disease.
This Anti-CD4 program is the subject of 41 issued and pending patents including composition of matter and method of use patents, which have been exclusively licensed from Thomas Jefferson University (TJU). This program has received substantial development support in the form of grants from the National Institutes of Health, as well as a $3.5 Million grant from the Trustees of Thomas Jefferson University.
CORRECTA(TM)
Pipex is developing CORRECTA(TM), a proprietary retention enema formulation of the widely used topical antifungal agent clotrimazole, for the treatment of acute refractory pouchitis, a subset of inflammatory bowel disease related to ulcerative colitis (UC). CORRECTA(TM) is currently the subject of a double-blinded, placebo-controlled, multi-center, four-week treatment period, phase II clinical trial for acute pouchitis. This clinical trial, called the "CAPTURE" study, is currently being funded by a $750,000 grant from the FDA's Orphan Drug Group. Pipex has expanded this study to additional clinical centers in order to increase enrollment and expedite completion of the study.
About the Transaction
The acquisition was consummated when EPI merged with and into a wholly owned subsidiary of Pipex, Effective Acquisition Corp., with EPI being the surviving corporation. In the transaction, Pipex issued approximately 2.29 million unregistered shares of common stock of Pipex, warrants and options (many of which are contingent upon various developmental and regulatory milestones being achieved) to purchase 695,183 shares of Pipex common stock to the minority shareholders of EPI comprising approximately thirty-three percent (33%) of EPI that Pipex did not already own.
They need to begin updating us on the Oklahoma wells, that will help the price also.
BIGN claimed a 15X increase, interval of time unknown. SBRX showed an 18X increase over the course of a month. Both have access to similar rework technonogy, BIGN also has access to hydroslotting.
I doubt that we will get 300 wells, we were told that 30 wells and 4 million would be our cut of the deal, currently producing 1.8 million/year without rework.
You tell me about the audit Joe, were they working on it?
Exactly.
Thay announced a 15X increase in flow rates and there is nothing new in the PR?
We also have some details as to why this is taking this long to close the deals. Verification that the wells are producing what the ETLOI company claims it is producing.
Plus Grimes.
#2 returns to it's original flow rate and that is what, .5 million a year to the revenues?
Right, they just announced a 15X increase in oil flow rate after rework and there is nothing new in the PR.
If this is the case then there is a 3 way 66% ownership between Martell and the 2 docs, am I right?
If we still have Grimes + TX + OK this will be an interesting stock for 2007.
I'm in for the long haul also, these guys are too big in their field to ignore.
I agree Penn. It appears that they even tied the ability to rework the wells into the LOI agreement. Lots of detials to finalize I guess. I was nice that they mentioned Grimes, although that now confuses how we get out share debt free, LOL.
I'l like to know what they did to rework the wells, what technologies were used. If they can do this on the Louisanna and Oklahoma wells we'll be looking good.
Looks like the new date for closing the LOI is the first quarter of this year. They'll need to update us on OK and other TX info during this time to keep the pps up.
I hope they keep this in mind
If they told us everything we wouldn't have anything to argue about.
3 barrels to 45 barrels! Nice.
News -
News for 'BIGN' - (Biogenerics Provides Update on East Texas LOI and
Grimes)
TYLER, Texas, Jan 11, 2007 (PrimeNewswire via COMTEX) -- Biogenerics Limited (Pink Sheets:BIGN) is pleased to update shareholders on the company's progress which is as follows:
East Texas Joint Venture Transaction: The Board of Directors is happy to announce that the East Texas Oil Field Joint Venture Transaction is still proceeding. The delay is due to the fact that currently, the transaction has now escalated to involve 2,714 acres of leases, over 300 wells with production projected to be over 15,000 bbls/oil/month within the first six months of the expected conclusion. Part of this transaction will include future well sites for offset drilling production on the current leases involving the Lower Stringer and Main Woodbine/Ashe Stringer zones.
Steps have been taken to complete initial field due diligence and obtain commitments from key employees for continued services. Currently, the Joint Venture Participants are working diligently to conclude the clearing of titles on all leases including all necessary State of Texas operator requirements. Management is examining and observing active well operations to determine future production capacities. In conjunction with this, an existing active well, which was producing 3 bbls/oil/day, was re-completed at the lower pay zone and is now producing over 45 bbls/day, increasing production by over 1,200 bbls/oil/month.
This test of increased production capacity verified the Joint Venture Participant's projections in its financial model. The Company expects that this transaction will reach a viable conclusion within the first quarter of this calendar year. Management continues to pursue this transaction as its
number one priority.
Hydroslotter/Grimes: Biogenerics Limited continues to build on its business relationship with Hydroslotter Corp. There have been some challenges with well No. 2 (Ophelia). Hydroslotter confirms the issues are unrelated to the Hydroslotting technology. It is expected Ophelia will return to its normal flow rates once the issues are resolved. Andreotti No. 1 is still producing at
its normal flow rates. Biogenerics looks forward to a continued working relationship with Hydroslotter as opportunities continue to present themselves.
Website: http:/www.bignltd.com
About Biogenerics Limited
Biogenerics is a diversified investment venture capital firm focused on
exploiting and distributing domestic oil and gas reserves. Biogenerics
also has
joint venture activities with Tyche Energy Inc. and Hydroslotter Corp.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of
the Private Securities Litigation Reform Act of 1995. Statements in this
release
that are forward-looking statements are based on current expectations and
assumptions that are subject to known and unknown risks, uncertainties, or
other
factors which may cause actual results, performance, or achievements of
the
company to be materially different from any future results, performance,
or
achievements expressed or implied by such forward-looking statements.
Actual
results could differ materially because of factors such as the effect of
general
economic and market conditions, entry into markets with vigorous
competition,
market acceptance of new products and services, continued acceptance of
existing
products and services, technological shifts, and delays in product
development
and related product release schedules, any of which may cause revenues and
income to fall short of anticipated levels. All information in this
release is
as of the date of this release. The company undertakes no duty to update
any
forward-looking statement to conform the statement to actual results or
changes
in the company's expectations.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Biogenerics Limited
By Staff
CONTACT: Biogenerics Limited James Lancaster, CEO
Corporate Inquiries: (903)-561-2446 Investor
Relations: www.bignltd.com
(C) Copyright 2006 PrimeNewswire, Inc. All rights reserved.
-0-
SUBJECT CODE: ACQUISITIONS
OIL
Mergers and Acquisitions
Source: Comtex Wall Street News
Compliments of Scottrade.com
It looks like many of his patents are based on early detectionf of cancer.
I was doing a little research this morning and found that he was placed on the BOD of two additional companies just within the last 3 months. My hands are full with one job, I don't nkow how he can do all this simultaneously.
Xenomics (XNOM)
http://www.prnewswire.co.uk/cgi/news/release?id=178175
Zila (ZILA)
http://phx.corporate-ir.net/phoenix.zhtml?c=95158&p=irol-newsArticle&ID=923953&highlight...
.14 x .18
I had a 90 minute meeting and missed the big run for the most part. Looking good.
From redhotpennystocks.com, 'news' being sent out.
Champions Sports Inc (OTCBB: CSBR) does not have significant operations. The company intends to serve as a vehicle to effect a new business or a business combination with a private entity. Previously, it operated a sports bar restaurant in San Antonio, Texas. The company, formerly known as International Group, Inc., was founded in 1985 and changed its name to CHAMPIONS Sports, Inc. in 1986. CHAMPIONS Sports is based in Arlington, Virginia. With 16.82 million shares outstanding and 21,221 shares declared short as of November 2006, the failure to deliver in shares of CSBR has not been resolved and a buy-in is imminent.
Not much of a float at these prices. Nice.
Edit: boardmarks went from 8 to 39 overnight.
Grand Entertainment & Music, Inc. Announces Preproduction of Qbanito's Second French Album
MONTREAL, Jan 10, 2007 (MARKET WIRE via COMTEX) -- Grand Entertainment & Music,
Inc. (PINKSHEETS: GMSC) is pleased to announce that Qbanito is back in the
studios to record his second French album.
Qbanito has begun to work on his much anticipated second album, the follow up to
his debut "Partir." Once again, Qbanito will be working along side of famed
producer Jesus "El Nino" Perez on this project. All of the music demos have been
completed, and the artist is now in the studios recording. The new album will
have the same style and emotion as "Partir," adding a blend of African beats and
more traditional Cuban rhythms to give this album a different flavor. Last week,
Qbanito completed photo shoots for the album cover and promotional materials.
Grand Entertainment, in conjunction with TOX Records Canada, is planning to
release the album in April. The company is looking to have the album in stores
this spring, in time to book a promotional summer tour.
"I am pleased to see Qbanito back in the studios and hard at work on this follow
up album," stated President, Fred Berlin. "I am certain that his fans are going
to love this album as much, if not more than 'Partir.' So far production and
recording has gone well, so I do anticipate a spring time release. After hearing
the demo tracks, I must say that I am very excited to get this follow up album
released."
About Grand Entertainment & Music, Inc.
Based in Montreal, Canada and incorporated in November 1998, the Company is an
independent music entity that produces, promotes, markets and controls the
copyrights on music recordings in multiple formats. Additionally, The Company's
multi-million dollar studio, Cherry Studios, has produced voice-overs and sound
tracks for commercials and film. In addition, Cherry Studios has also produced
thousands of recordings and has to its credit a total of 23 gold and platinum
albums. GEM has recently found success in the reggaeton market with its
signature artist, Qbanito. Qbanito's debut album has already generated a #1 hit
in Canada and is currently being marketed by Universal Music in Europe. Grand
Entertainment also controls exclusive rights to vast catalogues of previously
unreleased recordings from Cuban music archives. In November 2006, Grand
Entertainment acquired half of Lost City Records, adding a half dozen
award-winning artists, including rising rap star Big Lou, and a 500+ song
catalogue to Grand's existing assets. In addition, the company will continue to
focus on growth through acquisitions over the next twelve months in an effort to
reach its mission of becoming a premier production, recording, publishing, and
internet distribution company.
Safe Harbor Statement
This release contains forward-looking statements with respect to the results of
operations and business of Grand Entertainment & Music (GEM) Inc., which
involves risks and uncertainties. The Company's actual future results could
materially differ from those discussed. The company intends that such statements
about the Company's future expectations, including future revenues and earnings,
and all other forward-looking statements be subject to the "Safe Harbors"
provision of the Private Securities Litigation Reform Act of 1995.
This show him still at IMClone in early 2006 in the same Vice Chairman position.
http://bostonsec.stockgroup.com/files.php?TK=IMCL&st=1
A little background on Sidransky, 12 patents to his name.
(assuming it's the same doctor)
http://72.14.253.104/search?q=cache:LymSgEcfw4kJ:144.82.123.1/iaoo/founders/Sidransky%2520D_ShortCV.....
I'm in at .07 after the ShellStockReview email. I get quite a few hits on these two doctors from google, they have publications regarding 'Mitochondrial Mutation Detection' that seem to be in many of the medical online libraries.
GLTA
Nice PR.
I also just noticed the updated IBOX, great job.
These are small orders.
The 2.95 orders were never posted at 'Last' prices, may have made a difference.
Specs is a liquor store chain in Texas, they have a number of stores in the Houston and Austin area and are well known here. They are mentioned in the message below ...
http://www.investorshub.com/boards/read_msg.asp?Message_id=15963584&txt2find=specs
$7.18 is my guess.
Net yet, I was told by Specs to call back this week.
Thanks very much for your help.
How does one estimate an approximate PPS on a company given the following:
OS = 105,000,000
estimated annual pretax earnings = $3 million
no idea what the PE should be, but it's a pinksheet company.
float is 45,000,000.
I realize that any guess would just be a wild guess since it doesn't take into consideration a lot of things (liabilities, management, etc) but I'm trying to find a starting place.
What other info would be needed if this isn't enough?
Thanks,
Rich
Sorry, posted this to the wrong board. Too late to delete.
How does one estimate an approximate PPS on a company given the following:
OS = 105,000,000
estimated annual pretax earnings = $3 million
no idea what the PE should be, but it's a pinksheet company.
float is 45,000,000.
What other info would be needed?
Thanks,
Rich